Spyre Therapeutics, Inc. (SYRE)

Spyre Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Year	Current	2023	2022	2021	2020	2019
Market Capitalization	1,294	87	28	234	377	221
Market Cap Growth	7130.34%	214.86%	-88.19%	-37.90%	70.36%	23.39%
Enterprise Value	796	-252	-25	144	235	153
PE Ratio	-	-0.26	-0.33	-3.56	-4.66	-2.83
PS Ratio	1861.53	98.34	11.88	12.50	-	-
PB Ratio	8.41	0.47	0.55	2.79	2.70	3.69
P/FCF Ratio	-12.43	-0.88	-0.35	-4.32	-4.71	-3.30
P/OCF Ratio	-12.37	-0.87	-0.35	-4.36	-4.98	-3.37
EV/Sales Ratio	1156.65	-284.95	-10.72	7.70	-	-
EV/EBITDA Ratio	-2.44	0.75	0.30	-2.27	-2.96	-1.98
EV/EBIT Ratio	-2.43	0.75	0.30	-2.20	-2.90	-1.96
EV/FCF Ratio	-8.03	2.54	0.31	-2.66	-2.93	-2.28
Debt / Equity Ratio	-	-	0.09	0.06	0.04	0.08
Debt / EBITDA Ratio	-	-	-0.06	-0.08	-0.07	-0.07
Debt / FCF Ratio	-	-	-0.06	-0.09	-0.07	-0.08
Quick Ratio	11.33	10.62	3.93	4.75	9.01	4.00
Current Ratio	11.38	10.68	4.25	4.91	9.11	4.06
Asset Turnover	0.00	0.00	0.03	0.14	0	0
Return on Equity (ROE)	1250.70%	576.40%	-127.10%	-61.40%	-68.70%	-88.00%
Return on Assets (ROA)	-113.80%	-160.40%	-95.10%	-47.90%	-58.30%	-72.90%
Return on Capital (ROIC)	-178.15%	-131.67%	-154.33%	-73.78%	-56.09%	-123.32%
Earnings Yield	-28.44%	-388.82%	-302.87%	-28.09%	-21.44%	-35.34%
FCF Yield	-8.62%	-114.12%	-289.74%	-23.17%	-21.22%	-30.34%
Buyback Yield / Dilution	-868.38%	-104.59%	-28.19%	-23.18%	-67.05%	-53.44%
Total Shareholder Return	-868.38%	-104.59%	-28.19%	-23.18%	-67.05%	-53.44%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).